today the Republic occupies the sixth place in the list of regions with the largest number of cases of coronavirus infection. “In Dagestan was a difficult epidemiological situation, – said Anatoly Chubais. Therefore, RUSNANO sent to the Republic with a large consignment of high-precision tests, development and mass production which quickly organized our Ulyanovsk project “Testgen”. Test system allows in terms of standard PCR laboratories for two hours to make the 96 analyses”.
According to the head of RUSNANO, the purchase of test-systems of “Testgen” were sent to money raised by the employees, as well as funds allocated by the company for charitable assistance.
“I am grateful to the Group of “RUSNANO”, who donated personal funds to purchase the first batch of tests for Dagestan, – said Anatoly Chubais. – I hope that our assistance will help to accelerate the detection of diseases COVID-19 and to slow down the speed of propagation of the virus.”
Tests passed the Republic of Dagestan is an innovative development of Russian scientists, but rather of “Testgen” from Ulyanovsk nanocenter ULNANOTECH, which is included in investment Fund for infrastructure and educational programs “RUSNANO”. Test system is able to show the presence or absence of RNA of SARS-CoV-2 in the early stages and with high accuracy over 96%. In addition, the test result can be obtain in just two hours.
the Russian test-system has received not only national but European certificates of conformity, which indicates its high quality. In addition, the company now is a manufacturer of tests is working to develop a automation process of laboratory analysis, eliminating one of the main causes of “false-positive and false-negative results, “the human factor”.
today the company “Testgen” capable of producing 1-1. 5 million tests per month. In the future, this number may be increased to 2 million tests.
the Funds allocated for the purchase of test systems for the Republic of Dagestan is not the only charity event company RUSNANO, aims to combat coronavirus infection. Previously, the company allocated 4 million rubles to the National Association of experts in primary immunodeficiencies (of NAAPID) to support clinical studies aimed at studying the state of the blood coagulation system in patients with COVID-19. As you know, the virus causes a bleeding disorder, making the course of the disease more severe. To identify these disorders at an early stage allows designed a portfolio company of “RUSNANO” ultrasensitive test “Cromodinamica” that can detect blood coagulation disorders and to help the doctor in about��Encke the effectiveness of treatment.
Another portfolio company of “RUSNANO” – “Mitotech” temporarily refocused its resources on a drug aimed at preventing the development of acute respiratory distress syndrome in patients COVID-19. As a result of this complication often requires the connection of the patient to a ventilator.
But perhaps the biggest challenge for scientists today is the development of a vaccine. And a portfolio company of “RUSNANO” “pharmsynthez” together with the Institute of Bioorganic chemistry. M. M. Shemyakin and Y. A. Ovchinnikov Russian Academy of Sciences (IBCH) plan before the end of 2020 to create such a drug. Creating vaccines is a unique technology that will contribute to the formation of long and stable immune system.
